Immunic (IMUX) Competitors $0.92 -0.06 (-5.71%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. RVNC, VERV, MBX, AUTL, TKNO, CMPS, ORKA, CYRX, CKPT, and SNDLShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Revance Therapeutics (RVNC), Verve Therapeutics (VERV), MBX Biosciences (MBX), Autolus Therapeutics (AUTL), Alpha Teknova (TKNO), COMPASS Pathways (CMPS), Oruka Therapeutics (ORKA), Cryoport (CYRX), Checkpoint Therapeutics (CKPT), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Revance Therapeutics Verve Therapeutics MBX Biosciences Autolus Therapeutics Alpha Teknova COMPASS Pathways Oruka Therapeutics Cryoport Checkpoint Therapeutics SNDL Immunic (NASDAQ:IMUX) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Which has more volatility and risk, IMUX or RVNC? Immunic has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Does the MarketBeat Community favor IMUX or RVNC? Revance Therapeutics received 289 more outperform votes than Immunic when rated by MarketBeat users. However, 65.50% of users gave Immunic an outperform vote while only 59.41% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes11265.50% Underperform Votes5934.50% Revance TherapeuticsOutperform Votes40159.41% Underperform Votes27440.59% Which has higher earnings and valuation, IMUX or RVNC? Immunic has higher earnings, but lower revenue than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-0.75Revance Therapeutics$234.04M1.63-$323.99M-$1.93-1.89 Do analysts rate IMUX or RVNC? Immunic presently has a consensus price target of $13.20, indicating a potential upside of 1,337.91%. Revance Therapeutics has a consensus price target of $8.45, indicating a potential upside of 131.51%. Given Immunic's stronger consensus rating and higher probable upside, research analysts clearly believe Immunic is more favorable than Revance Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Revance Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the media refer more to IMUX or RVNC? In the previous week, Immunic had 4 more articles in the media than Revance Therapeutics. MarketBeat recorded 4 mentions for Immunic and 0 mentions for Revance Therapeutics. Immunic's average media sentiment score of 0.63 beat Revance Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media. Company Overall Sentiment Immunic Positive Revance Therapeutics Neutral Is IMUX or RVNC more profitable? Immunic has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% Revance Therapeutics -74.67%N/A -37.22% Do insiders & institutionals believe in IMUX or RVNC? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are owned by institutional investors. 3.0% of Immunic shares are owned by insiders. Comparatively, 5.1% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryImmunic beats Revance Therapeutics on 12 of the 18 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.10M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.748.9726.6219.77Price / SalesN/A253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book1.436.486.814.53Net Income-$93.61M$143.98M$3.23B$248.18M7 Day Performance-6.06%3.37%4.05%1.06%1 Month Performance-7.19%7.83%11.64%14.68%1 Year Performance-27.72%-2.24%17.11%6.87% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.4327 of 5 stars$0.92-5.7%$13.20+1,337.9%-24.5%$87.10MN/A-0.7470Earnings ReportGap DownRVNCRevance Therapeutics1.9451 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Analyst ForecastVERVVerve Therapeutics3.5594 of 5 stars$4.25+0.4%$25.75+506.6%-22.5%$379.30M$32.33M-1.73110Trending NewsEarnings ReportAnalyst RevisionGap DownMBXMBX Biosciences2.9921 of 5 stars$11.21+0.9%$37.50+234.7%N/A$374.52MN/A0.0036News CoveragePositive NewsAUTLAutolus Therapeutics3.2471 of 5 stars$1.40+5.7%$9.32+568.1%-61.9%$371.20M$10.12M-1.15330TKNOAlpha Teknova1.7799 of 5 stars$6.86-1.5%$8.50+24.0%+275.4%$367.94M$37.75M-9.30240Gap DownCMPSCOMPASS Pathways2.2485 of 5 stars$3.93+3.6%$20.20+414.6%-41.7%$366.29MN/A-1.79120Gap UpORKAOruka Therapeutics2.6029 of 5 stars$9.69+1.6%$39.86+311.3%N/A$364.30MN/A-1.55N/ANews CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCYRXCryoport3.0349 of 5 stars$7.15+1.2%$11.00+53.8%-43.2%$357.98M$214.83M-2.111,020CKPTCheckpoint Therapeutics1.9457 of 5 stars$4.17-0.1%$4.33+4.0%+104.9%$348.88M$41,000.00-2.2610News CoverageNegative NewsSNDLSNDL3.1393 of 5 stars$1.33+2.7%$3.63+173.6%-44.6%$348.44M$927.61M-4.28580News CoveragePositive News Related Companies and Tools Related Companies Revance Therapeutics Alternatives Verve Therapeutics Alternatives MBX Biosciences Alternatives Autolus Therapeutics Alternatives Alpha Teknova Alternatives COMPASS Pathways Alternatives Oruka Therapeutics Alternatives Cryoport Alternatives Checkpoint Therapeutics Alternatives SNDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMUX Stock Free IMUX Stock Alerts